The trifunctional antibody (trAb) catumaxomab (Removab®, Fresenius Biotech GmbH, Munich, Germany) was approved in the European Union in April 2009 for the intraperitoneal (i.p.)treatment of malignant ascites in patients with epithelial cell-adhesion molecule (EpCAM)-positive carcinomas. The gene discussed is EPCAM; the disease is carcinoma.